(Q34495213)

2 August 2017

1 reference

title

Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

2 August 2017

0 references

1 reference

Delmas PD

1

1 reference

2 August 2017

publication date

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

volume

30

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

14-17

1 reference

Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Hormone replacement therapy in the prevention and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

The relative contribution of trabecular and cortical bone to the strength of human lumbar vertebrae

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

The Role of Estrogen in the Control of Rat Osteocyte Apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2801%2900667-6

7 January 2021

10.1016/S8756-3282(01)00667-6

Identifiers

DOI

1 reference

2 August 2017

1 reference